Published in J Exp Med on December 01, 1978
Neutrophil activation on biological surfaces. Massive secretion of hydrogen peroxide in response to products of macrophages and lymphocytes. J Clin Invest (1987) 4.80
T-cell-mediated suppression of anti-tumor immunity. An explanation for progressive growth of an immunogenic tumor. J Exp Med (1980) 3.17
Generation and characterization of a lipopolysaccharide-induced and serum-derived cytotoxic factor for tumor cells. Infect Immun (1980) 2.12
Mechanisms of anti-tumor action of Corynebacterium parvum. I. Potentiated tumor-specific immunity and its therapeutic limitations. J Exp Med (1981) 1.77
The antitumor function of tumor necrosis factor (TNF), I. Therapeutic action of TNF against an established murine sarcoma is indirect, immunologically dependent, and limited by severe toxicity. J Exp Med (1988) 1.77
Mechanisms of syngeneic tumor rejection. Susceptibility of host-selected progressor variants to various immunological effector cells. J Exp Med (1982) 1.73
Elimination of syngeneic sarcomas in rats by a subset of T lymphocytes. J Exp Med (1980) 1.72
Expression of passively transferred immunity against an established tumor depends on generation of cytolytic T cells in recipient. Inhibition by suppressor T cells. J Exp Med (1983) 1.46
The immunological basis of endotoxin-induced tumor regression. Requirement for a pre-existing state of concomitant anti-tumor immunity. J Exp Med (1978) 1.43
The specificity of suppressor T cells induced by chronic Mycobacterium avium infection in mice. Clin Exp Immunol (1981) 1.42
The antitumor function of tumor necrosis factor (TNF) II. Analysis of the role of endogenous TNF in endotoxin-induced hemorrhagic necrosis and regression of an established sarcoma. J Exp Med (1988) 1.27
CD8+ T cell priming by dendritic cell vaccines requires antigen transfer to endogenous antigen presenting cells. PLoS One (2010) 1.18
Subtherapeutic numbers of tumour-sensitized, L3T4+, Ly 1+2- T cells are needed for endotoxin to cause regression of an established immunogenic tumour. Immunology (1987) 1.06
Growing tumors induce hypersensitivity to endotoxin and tumor necrosis factor. Infect Immun (1987) 1.06
Toll-like receptors, tissue injury, and tumourigenesis. Mediators Inflamm (2010) 0.96
Increased toxicity of endotoxin for tumor-bearing mice and mice responding to bacterial pathogens: macrophage activation as a common denominator. Infect Immun (1980) 0.95
Antitumour responses to flavone-8-acetic acid and 5,6-dimethylxanthenone-4-acetic acid in immune deficient mice. Br J Cancer (1992) 0.95
The antibody-based targeted delivery of TNF in combination with doxorubicin eradicates sarcomas in mice and confers protective immunity. Br J Cancer (2013) 0.84
In vivo activity of tumor necrosis factor (TNF) mutants. Secretory but not membrane-bound TNF mediates the regression of retrovirally transduced murine tumor. J Immunol (1992) 0.81
Induction of C3b-mediated phagocytosis in macrophages by distinct populations of lipopolysaccharide-stimulated lymphocytes. Infect Immun (1981) 0.81
Generation of enhanced macrophage-mediated antibacterial resistance in animals responding to tumor allografts. Infect Immun (1982) 0.80
Anti-tumour activity of low-toxicity lipopolysaccharide of Bordetella pertussis. Br J Cancer (1994) 0.76
Potentiation of tumour growth by endotoxin in serum from syngeneic tumour-bearing mice. Br J Cancer (1980) 0.75
Tumor reductive therapies and antitumor immunity. Oncotarget (2017) 0.75
An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A (1975) 23.42
Importance of thymus-derived lymphocytes in cell-mediated immunity to infection. Cell Immunol (1973) 7.68
Absorption of guinea pig serum with agar. A method for elimination of itscytotoxicity for murine thymus cells. Transplantation (1970) 5.37
Similarities of the anti-tumour actions of endotoxin, lipid A and double-stranded RNA. Br J Cancer (1973) 4.65
Partial purification of a serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A (1976) 2.42
II. Contribution to the Knowledge of Sarcoma. Ann Surg (1891) 2.21
Corynebacterium parvum as the priming agent in the production of tumor necrosis factor in the mouse. J Natl Cancer Inst (1977) 2.15
T-cell-mediated concomitant immunity to syngeneic tumors. I. Activated macrophages as the expressors of nonspecific immunity to unrelated tumors and bacterial parasites. J Exp Med (1977) 1.93
Induction and immunological properties of tumor necrosis factor. J Reticuloendothel Soc (1978) 1.53
Inflammatory cells in solid murine neoplasms. I. Tumor disaggregation and identification of constituent inflammatory cells. Int J Cancer (1976) 1.39
Immunotherapy of an intramuscular tumor in strain-2 guinea pigs: prevention of tumor growth by intradermal immunization and by systemic transfer of tumor immunity. J Natl Cancer Inst (1970) 1.14
Identification of nitric oxide synthase as a protective locus against tuberculosis. Proc Natl Acad Sci U S A (1997) 7.90
Importance of thymus-derived lymphocytes in cell-mediated immunity to infection. Cell Immunol (1973) 7.68
The relative importance of blood monocytes and fixed macrophages to the expression of cell-mediated immunity to infection. J Exp Med (1970) 7.13
Cellular mediators of anti-Listeria immunity as an enlarged population of short lived, replicating T cells. Kinetics of their production. J Exp Med (1973) 5.94
Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med (1982) 5.47
The relative importance of T cell subsets in immunity and immunopathology of airborne Mycobacterium tuberculosis infection in mice. J Exp Med (2001) 4.50
Neutrophils are essential for early anti-Listeria defense in the liver, but not in the spleen or peritoneal cavity, as revealed by a granulocyte-depleting monoclonal antibody. J Exp Med (1994) 4.16
Cellular kinetics associated with the development of acquired cellular resistance. J Exp Med (1969) 3.94
The concept of the activated macrophage. J Immunol (1978) 3.69
Early gamma interferon production by natural killer cells is important in defense against murine listeriosis. Infect Immun (1991) 3.59
Early pathogenesis of infection in the liver with the facultative intracellular bacteria Listeria monocytogenes, Francisella tularensis, and Salmonella typhimurium involves lysis of infected hepatocytes by leukocytes. Infect Immun (1992) 3.52
Virulence ranking of some Mycobacterium tuberculosis and Mycobacterium bovis strains according to their ability to multiply in the lungs, induce lung pathology, and cause mortality in mice. Infect Immun (1995) 3.31
The mitotic potential of fixed phagocytes in the liver as revealed during the development of cellular immunity. J Exp Med (1969) 3.30
The histogenesis of immunologically committed lymphocytes. Cell Immunol (1972) 3.29
T-cell-mediated suppression of anti-tumor immunity. An explanation for progressive growth of an immunogenic tumor. J Exp Med (1980) 3.17
T cell dependence of macrophage activation and mobilization during infection with Mycobacterium tuberculosis. Infect Immun (1974) 3.16
Resistance ranking of some common inbred mouse strains to Mycobacterium tuberculosis and relationship to major histocompatibility complex haplotype and Nramp1 genotype. Immunology (1998) 2.91
The action of cortisone acetate on cell-mediated immunity to infection. Suppression of host cell proliferation and alteration of cellular composition of infective foci. J Exp Med (1971) 2.89
Neutrophils are critical for host defense against primary infection with the facultative intracellular bacterium Francisella tularensis in mice and participate in defense against reinfection. Infect Immun (1994) 2.61
Neutrophil-mediated dissolution of infected host cells as a defense strategy against a facultative intracellular bacterium. J Exp Med (1991) 2.55
Nature of "memory" in T-cell mediated antibacterial immunity: cellular parameters that distinguish between the active immune response and a state of "memory". Infect Immun (1975) 2.50
Generation and decay of the immune response to a progressive fibrosarcoma. I. Ly-1+2- suppressor T cells down-regulate the generation of Ly-1-2+ effector T cells. J Exp Med (1984) 2.44
On the mechanism of T cell-independent anti-Listeria resistance in nude mice. J Immunol (1980) 2.20
Nature of "memory" in T-cell-mediated antibacterial immunity: anamnestic production of mediator T cells. Infect Immun (1975) 2.16
Evidence inconsistent with a role for the Bcg gene (Nramp1) in resistance of mice to infection with virulent Mycobacterium tuberculosis. J Exp Med (1996) 2.14
The uptake of particulate antigens. J Reticuloendothel Soc (1968) 2.07
Inflammatory lymphocyte in cell-mediated antibacterial immunity: factors governing the accumulation of mediator T cells in peritoneal exudates. Infect Immun (1974) 2.02
The action of cortisone acetate on cell-mediated immunity to infection: histogenesis of the lymphoid cell response and selective elimination of committed lymphocytes. Cell Immunol (1972) 1.95
T-cell-mediated concomitant immunity to syngeneic tumors. I. Activated macrophages as the expressors of nonspecific immunity to unrelated tumors and bacterial parasites. J Exp Med (1977) 1.93
Resolution of primary murine listeriosis and acquired resistance to lethal secondary infection can be mediated predominantly by Thy-1+ CD4- CD8- cells. J Infect Dis (1991) 1.90
Advantages of measuring changes in the number of viable parasites in murine models of experimental cutaneous leishmaniasis. Infect Immun (1983) 1.90
T cell-mediated immunosuppression as an obstacle to adoptive immunotherapy of the P815 mastocytoma and its metastases. J Exp Med (1981) 1.87
High level monocyte chemoattractant protein-1 expression in transgenic mice increases their susceptibility to intracellular pathogens. J Immunol (1995) 1.87
Down-regulation of the antitumor immune response. Adv Cancer Res (1985) 1.84
Mechanisms of anti-tumor action of Corynebacterium parvum. I. Potentiated tumor-specific immunity and its therapeutic limitations. J Exp Med (1981) 1.77
The antitumor function of tumor necrosis factor (TNF), I. Therapeutic action of TNF against an established murine sarcoma is indirect, immunologically dependent, and limited by severe toxicity. J Exp Med (1988) 1.77
Elimination of CD4+ suppressor T cells from susceptible BALB/c mice releases CD8+ T lymphocytes to mediate protective immunity against Leishmania. J Exp Med (1989) 1.77
Endocytosis. Semin Hematol (1970) 1.63
Suppression of cell-mediated immunity to infection by an antimitotic drug. Further evidence that migrant macrophages express immunity. J Exp Med (1970) 1.61
Subversion of host defense mechanisms by murine tumors. I. A circulating factor that suppresses macrophage-mediated resistance to infection. J Exp Med (1976) 1.56
Genetically susceptible mice remain proportionally more susceptible to tuberculosis after vaccination. Immunology (1999) 1.52
The requirement of tumour necrosis factor-alpha and interferon-gamma for the expression of protective immunity to secondary murine tularaemia depends on the size of the challenge inoculum. Microbiology (1996) 1.51
CD4+ and CD8+ T-cell-dependent and -independent host defense mechanisms can operate to control and resolve primary and secondary Francisella tularensis LVS infection in mice. Infect Immun (1994) 1.50
Mechanisms of anti-tumor action of Corynebacterium parvum. II. Potentiated cytolytic T cell response and its tumor-induced suppression. J Exp Med (1981) 1.47
Immunological control of macrophage proliferation in vivo. Infect Immun (1973) 1.46
Expression of passively transferred immunity against an established tumor depends on generation of cytolytic T cells in recipient. Inhibition by suppressor T cells. J Exp Med (1983) 1.46
The Nramp1 antimicrobial resistance gene segregates independently of resistance to virulent Mycobacterium tuberculosis. Immunology (1996) 1.44
The immunological basis of endotoxin-induced tumor regression. Requirement for a pre-existing state of concomitant anti-tumor immunity. J Exp Med (1978) 1.43
Genetic control of susceptibility to infection with Mycobacterium tuberculosis in mice. Genes Immun (2000) 1.38
Selective radiation resistance of immunologically induced T cells as the basis for irradiation-induced T-cell-mediated regression of immunogenic tumor. J Leukoc Biol (1991) 1.37
Persistent infection with virulent but not avirulent Mycobacterium tuberculosis in the lungs of mice causes progressive pathology. J Med Microbiol (1996) 1.37
Mchanisms of antitumor action of Corynebacterium parvum: nonspecific tumor cell destruction at site of immunologically mediated sensitivity reaction to C. parvum. J Natl Cancer Inst (1975) 1.35
The murine antitumor immune response and its therapeutic manipulation. Adv Immunol (1984) 1.33
Methyl green-pyronin for staining autoradiographs of hydroxyethyl methacrylate-embedded lymphoid tissue. Stain Technol (1971) 1.32
Cyclophosphamide-induced immunologically mediated regression of a cyclophosphamide-resistant murine tumor: a consequence of eliminating precursor L3T4+ suppressor T-cells. Cancer Res (1989) 1.31
Non-H-2 restriction of expression of passively transferred delayed sensitivity. J Exp Med (1982) 1.27
Gamma-irradiation facilitates the expression of adoptive immunity against established tumors by eliminating suppressor T cells. Cancer Immunol Immunother (1984) 1.27
The localization by electron microscopy of nucleoside phosphatase activity in guinea pig phagocytic cells. J Ultrastruct Res (1966) 1.26
Adoptive immunization against an established tumor with cytolytic versus memory T cells. Immediate versus delayed onset of regression. Transplantation (1984) 1.25
Immunologic consequences of antibiotic-induced abridgement of bacterial infection: effect on generation and loss of protective T cells and level of immunologic memory. J Immunol (1981) 1.22
Roles of Listeria monocytogenes virulence factors in survival: virulence factors distinct from listeriolysin are needed for the organism to survive an early neutrophil-mediated host defense mechanism. Infect Immun (1992) 1.21
Subversion of host defense mechanisms by murine tumors. II. Counter-influence of concomitant antitumor immunity. J Exp Med (1976) 1.17
Leukocyte-mediated lysis of infected hepatocytes during listeriosis occurs in mice depleted of NK cells or CD4+ CD8+ Thy1.2+ T cells. Infect Immun (1993) 1.10
Ly 1+2- suppressor T cells down-regulate the generation of Ly 1-2+ effector T cells during progressive growth of the P815 mastocytoma. Immunology (1985) 1.08
Subtherapeutic numbers of tumour-sensitized, L3T4+, Ly 1+2- T cells are needed for endotoxin to cause regression of an established immunogenic tumour. Immunology (1987) 1.06
Generation and decay of the immune response to a progressive fibrosarcoma. II. Failure to demonstrate postexcision immunity after the onset of T cell-mediated suppression of immunity. J Exp Med (1984) 1.04
Suppressive effect of bacterial endotoxin on the expression of cell-mediated anti-Listeria immunity. Infect Immun (1979) 1.02
The therapeutic significance of concomitant antitumor immunity. I. LY-1-2+ T cells from mice with a progressive tumor can cause regression of an established tumor in gamma-irradiated recipients. Cancer Immunol Immunother (1984) 1.01
Mechanisms of antitumor action of Corynebacterium parvum: replicating short-lived T cells as the mediators of potentiated tumor-specific immunity. J Reticuloendothel Soc (1976) 0.99
The localization by electron microscopy of acid phosphatase activity in guinea pig macrophages. J Ultrastruct Res (1966) 0.98
The therapeutic significance of concomitant antitumor immunity. II. Passive transfer of concomitant immunity with Ly-1+2- T cells primes established tumors in T cell-deficient recipients for endotoxin-induced regression. Cancer Immunol Immunother (1984) 0.98
T cell suppressors of antitumor immunity. The production of Ly-1-,2+ suppressors of delayed sensitivity precedes the production of suppressors of protective immunity. J Exp Med (1986) 0.98
Subversion of host defense mechanisms by malignant tumors: an established tumor as a privileged site for bacterial growth. J Exp Med (1977) 0.97
Immunological consequences of tumor excision: from active immunity to immunological memory. Int J Cancer (1986) 0.96
Effect of aging on antimicrobial immunity: old mice display a normal capacity for generating protective T cells and immunologic memory in response to infection with Listeria monocytogenes. J Immunol (1985) 0.96
Increased toxicity of endotoxin for tumor-bearing mice and mice responding to bacterial pathogens: macrophage activation as a common denominator. Infect Immun (1980) 0.95
Listeria monocytogenes, but not Salmonella typhimurium, elicits a CD18-independent mechanism of neutrophil extravasation into the murine peritoneal cavity. Infect Immun (1994) 0.95
The importance of route of infection in determining the extent of exacerbation of listeriosis by anti-interferon-gamma monoclonal antibody. J Interferon Res (1991) 0.94
Limitations of the adoptive immunity assay for analyzing anti-Listeria immunity. J Infect Dis (1991) 0.93
Models of adoptive T-cell-mediated regression of established tumors. Contemp Top Immunobiol (1984) 0.92
Sublethal, whole-body ionizing irradiation can be tumor promotive or tumor destructive depending on the stage of development of underlying antitumor immunity. Cancer Immunol Immunother (1988) 0.89
Suppression of generation of concomitant antitumor immunity by passively transferred suppressor T cells from tumor-bearing donors. Cancer Immunol Immunother (1985) 0.87
Endotoxin-mediated necrosis and regression of established tumours in the mouse. A correlative study of quantitative changes in blood flow and ultrastructural morphology. Cancer Immunol Immunother (1986) 0.87
Mechanisms of antitumor action of Corynebacterium parvum: the generation of cell-mediated tumor specific immunity. J Reticuloendothel Soc (1976) 0.87
Tumor inhibition in mice by lipopolysaccharide-induced peritoneal cells and an induced soluble factor. Infect Immun (1976) 0.87
Specificity of the T cells that mediate and suppress adoptive immunotherapy of established tumors. J Leukoc Biol (1984) 0.86
The additive effects on the spreading of guinea pig macrophages of exogenous ATP and a surface coated with antigen-antibody molecules. Exp Cell Res (1969) 0.85